Results from the Children’s Oncology Group (COG) AML trials showed that benefit from GO at a single dose of 3 mg/m 2 at first induction and then intensification 9 was restricted to paediatric patients ...

Suppressing CD33 stimulates phagocytosis, slows plaque growth. A protective CD33 mutation could be a gain of function that activates phagocytosis. The CD33 receptor acts as a dimer. At the 14th ...

Clearly, additional investigations are needed to fully characterize the clinical significance of CD33 surface expression and the relevance of CD33-independent pathways of GO uptake. Further insights ...

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I) CD33 splicing single nucleotide polymorphism was evaluated in ...

Acute myeloid leukemia (AML) is one of the most common forms of cancer in children and adults. CD33, a protein often expressed on the surface of leukemic cells, has been a long-standing target for AML ...

M2T-CD33 has received orphan drug designation for AML, offering incentives like tax credits and market exclusivity. The M2T platform is a novel immunotherapy approach targeting CD33-positive leukemic ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA granted fast track designation to ...

SAN CARLOS, Calif., Nov. 19, 2025 /PRNewswire/ -- Aperture Therapeutics, a biotechnology company pioneering next-generation precision medicines for neurodegenerative diseases, today announced the ...

The positive preliminary SENTI-202 clinical data was presented on April 27 in a Clinical Trials Oral Minisymposium at the American Association for Cancer Research (AACR) Annual Meeting 2025 in an ...

Signaling through the CD33 receptor counteracts the known beneficial microglial responses to plaques, while clusterin is thought to promote Aβ aggregation. Up until now, these two AD risk factors were ...